Driven to extend the lives of cancer patients
Celcuity was founded in 2012 by Brian Sullivan and Lance Laing, PhD, to develop a better way to diagnose and treat the cellular abnormalities that drive tumor growth. Our team of drug development scientists, biochemists, molecular biologists, and diagnostics experts are advancing new targeted therapies for cancer using an integrated therapeutic and companion diagnostic strategy that leverages our CELsignia platform.
Integrated therapeutic and functional cellular analysis strategy to improve patient outcomes
Gedatolisib, our potential first-in-class pan-PI3K/mTOR inhibitor, is currently being developed to treat HR+/HER2- advanced breast cancer and metastatic castration resistant prostate cancer. With our functional cellular analysis platforms, we are characterizing abnormal cell activity to identify other tumor types and non-oncology diseases that gedatolisib may be able to treat efficaciously.
With our CELsignia companion diagnostic platform, we are collaborating with leading pharmaceutical companies to evaluate their targeted therapeutics in CELsignia-selected patients.